Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Sudarshan R. Iyer"'
Autor:
Sudarshan R Iyer, Kevin Nusser, Kristen Jones, Pushkar Shinde, Clare Keddy, Catherine Z Beach, Erin Aguero, Jeremy Force, Ujwal Shinde, Monika A Davare
Publikováno v:
EMBO Molecular Medicine, Vol 15, Iss 10, Pp n/a-n/a (2023)
Abstract ROS1 is the largest receptor tyrosine kinase in the human genome. Rearrangements of the ROS1 gene result in oncogenic ROS1 kinase fusion proteins that are currently the only validated biomarkers for targeted therapy with ROS1 TKIs in patient
Externí odkaz:
https://doaj.org/article/808793d75f2f413c9604e051833dd047
Autor:
Monika A. Davare, Romel Somwar, Marc Ladanyi, Gregory J. Riely, Alexander Drilon, Inna Khodos, Elisa de Stanchina, Marissa S. Mattar, Evan Siau, Adam J. Schoenfeld, Igor Odintsov, Sudarshan R. Iyer
Supplementary Figure from MYC Promotes Tyrosine Kinase Inhibitor Resistance in ROS1-Fusion-Positive Lung Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14cd1cbc3ae3a642d3da55c2f8fffbf3
https://doi.org/10.1158/1541-7786.22527461.v1
https://doi.org/10.1158/1541-7786.22527461.v1
Autor:
Monika A. Davare, Romel Somwar, Marc Ladanyi, Gregory J. Riely, Alexander Drilon, Inna Khodos, Elisa de Stanchina, Marissa S. Mattar, Evan Siau, Adam J. Schoenfeld, Igor Odintsov, Sudarshan R. Iyer
Supplementary Data from MYC Promotes Tyrosine Kinase Inhibitor Resistance in ROS1-Fusion-Positive Lung Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::022a965ac8a56c0d552f81232d4c5fa9
https://doi.org/10.1158/1541-7786.22527473
https://doi.org/10.1158/1541-7786.22527473
Autor:
Brian J. Druker, Marc Ladanyi, Erwin G. Van Meir, Tom Mikkelson, Ana DeCarvalo, Stephen W. Gilheeney, Romel Somwar, Randy Woltjer, Nameeta Shah, Sudarshan R. Iyer, Jacob P. Wagner, Anupriya Agarwal, Jacob J. Henderson, Monika A. Davare
Purpose:Gliomas, a genetically heterogeneous group of primary central nervous system tumors, continue to pose a significant clinical challenge. Discovery of chromosomal rearrangements involving kinase genes has enabled precision therapy, and improved
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac87f9f393f9e1929c3e2e7237ccd871
https://doi.org/10.1158/1078-0432.c.6527165.v1
https://doi.org/10.1158/1078-0432.c.6527165.v1
Autor:
Brian J. Druker, Marc Ladanyi, Erwin G. Van Meir, Tom Mikkelson, Ana DeCarvalo, Stephen W. Gilheeney, Romel Somwar, Randy Woltjer, Nameeta Shah, Sudarshan R. Iyer, Jacob P. Wagner, Anupriya Agarwal, Jacob J. Henderson, Monika A. Davare
U118MG spheroid treated with 250nM lorlatinib for 72 hrs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0167d1ee01d4e33d2885d4bf381fe2dd
https://doi.org/10.1158/1078-0432.22469195.v1
https://doi.org/10.1158/1078-0432.22469195.v1
Autor:
Brian J. Druker, Marc Ladanyi, Erwin G. Van Meir, Tom Mikkelson, Ana DeCarvalo, Stephen W. Gilheeney, Romel Somwar, Randy Woltjer, Nameeta Shah, Sudarshan R. Iyer, Jacob P. Wagner, Anupriya Agarwal, Jacob J. Henderson, Monika A. Davare
Supplementary Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::113241d593567663683628769a8a1672
https://doi.org/10.1158/1078-0432.22469189.v1
https://doi.org/10.1158/1078-0432.22469189.v1
Autor:
Sudarshan R. Iyer, Igor Odintsov, Adam J. Schoenfeld, Evan Siau, Marissa S. Mattar, Elisa de Stanchina, Inna Khodos, Alexander Drilon, Gregory J. Riely, Marc Ladanyi, Romel Somwar, Monika A. Davare
Publikováno v:
Mol Cancer Res
Targeted therapy of ROS1-fusion-driven non–small cell lung cancer (NSCLC) has achieved notable clinical success. Despite this, resistance to therapy inevitably poses a significant challenge. MYC amplification was present in ∼19% of lorlatinib-res
Autor:
Sudarshan R. Iyer, Kevin Nusser, Kristen Jones, Pushkar Shinde, Catherine Z. Beach, Clare Keddy, Erin Aguero, Jeremy Force, Ujwal Shinde, Monika A. Davare
Chromosomal rearrangements ofROS1generate ROS1 tyrosine kinase fusion proteins that are established oncogenes predicting effectiveness of tyrosine kinase inhibitors (TKI) treatment. The cancer genome reveals nonsynonymous missense mutations inROS1,ho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::11e802b0922310d450acde7aec8df68a
https://doi.org/10.1101/2022.12.27.521482
https://doi.org/10.1101/2022.12.27.521482
Autor:
Sudarshan R. Iyer, Kevin Nusser, Kristen Jones, Pushkar Shinde, Catherine Z. Beach, Clare Keddy, Erin Aguero, Jeremy Force, Ujwal Shinde, Monika A. Davare
Publikováno v:
Cancer Research. 83:3926-3926
ROS1 encodes the largest receptor tyrosine kinase (RTK) in the human genome. Chromosomal rearrangements of the ROS1 gene generate oncogenic ROS1 fusion proteins that have been successfully targeted with tyrosine kinase inhibitors (TKIs), most notably